Ad Scientiam and Ceres Brain Therapeutics join forces to develop innovative digital biomarkers in Creatine Transporter Deficiency.

We are thrilled to announce that Ad Scientiam and Ceres Brain Therapeutics are launching a joint research program to develop new digital biomarkers for Creatine Transporter Deficiency Syndrome. Ad Scientiam, a global leader in digital biomarkers and Ceres Brain Therapeutics, a biotech company developing a drug candidate for a rare neurological disease, the Creatine Transporter Deficiency Syndrome, join forces to develop new digital biomarkers to optimize future clinical trials.

Share

Ad Scientiam is proud to announce its collaboration with Abata Therapeutics Read the article
en_USEnglish